Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses ; volume:15 ; number:1 ; day:11 ; month:7 ; year:2024 ; pages:1-19 ; date:12.2024
Nature Communications ; 15, Heft 1 (11.7.2024), 1-19, 12.2024
- Urheber
-
Malli Cetinbas, Naniye
Monnell, Travis
Soomer-James, Jahna
Shaw, Pamela
Lancaster, Kelly
Catcott, Kalli C.
Dolan, Melissa
Mosher, Rebecca
Routhier, Caitlin
Chin, Chen-Ni
Toader, Dorin
Duvall, Jeremy
Bukhalid, Raghida
Lowinger, Timothy B.
Damelin, Marc
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-024-49932-4
- URN
-
urn:nbn:de:101:1-2409282116012.020908983489
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:38 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Malli Cetinbas, Naniye
- Monnell, Travis
- Soomer-James, Jahna
- Shaw, Pamela
- Lancaster, Kelly
- Catcott, Kalli C.
- Dolan, Melissa
- Mosher, Rebecca
- Routhier, Caitlin
- Chin, Chen-Ni
- Toader, Dorin
- Duvall, Jeremy
- Bukhalid, Raghida
- Lowinger, Timothy B.
- Damelin, Marc
- SpringerLink (Online service)
Ähnliche Objekte (12)
Antibody–drug conjugates in solid tumors: a look into novel targets
Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
Improved Drug Delivery of next-generation Antibody-Drug Conjugates by utilizing tumor-associated proteases
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Control of tumor merastasis by endogenous type I interferons
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Antibody–drug conjugates in solid tumors: a look into novel targets
Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
Improved Drug Delivery of next-generation Antibody-Drug Conjugates by utilizing tumor-associated proteases
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Control of tumor merastasis by endogenous type I interferons
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Antibody–drug conjugates in solid tumors: a look into novel targets
Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
Improved Drug Delivery of next-generation Antibody-Drug Conjugates by utilizing tumor-associated proteases
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Control of tumor merastasis by endogenous type I interferons